| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 11, 2024 4:30 P.M. |
| Form: | S-1 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $7.00 → $0.20 | Buy → Hold | Aegis Capital |
| 7/8/2021 | $7.00 | Buy | Aegis Capital |
| 6/28/2021 | $6.00 | Buy | Maxim Group |
10-Q - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
8-K - Enveric Biosciences, Inc. (0000890821) (Filer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
Psychedelics biotech Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results of its EB-003 drug candidate to be delivered via oral administration. EB-003 is a new, neuroplastogenic molecule designed to treat serious mental health disorders without the hallucinogenic effect typically associated with DMT (N,N-Dimethyltryptamine) and other psychedelic compounds. The results indicate that oral administration of EB-003 provides significant brain exposure in rodent models at potential therapeutic doses. "We continue to believe that EB-003 is substantially differentiated from the various psychedelic-inspired compounds in development," stated Joseph Tucker, Ph.D., CEO of Enveric.
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to
-SEC Filing
Second biotechnology company to potentially out-license novel compounds from Enveric's portfolio of assets with possible significant milestone payments and royalties Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, is pleased to announce that it has signed two non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of cannabinoid-COX-2 conjugate compounds for both pharmaceutical and non-pharmaceutical applications for treatment of joint diseases. The term sheets c
30+ year pharmaceutical industry veteran joins Enveric's executive team to lead company's financial and capital markets activities. Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer, effective March 13, 2023. Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served as Chief Financial Officer for multiple biotechnology companies. As CFO, Mr. Coveney will be responsibl
Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Lynn Gallant to the position of Vice President, Clinical Operations. Ms. Gallant brings more than 25 years of clinical operations and trial management experience to Enveric and will work alongside Bob Dagher, M.D., Chief Medical Officer, to oversee the ongoing development of the company's EVM201
Product Development Highlights: Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Started IND-enabling preclinical activities for EB-002 and completed important repeat-dose toxicology studies, genotoxicity studies, and key cardiac, respiratory, and CNS safety pharmacology studies. Corporate and Business Development Highlights: Signed three non-binding term sheets with an undisclosed biotechnology company to pursue the out-licensing of three classes of compounds from the Company's extensive portfolio of assets. Signe
Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety disorder and EVM301 Series Announced termination of proposed spin-off of cannabinoid clinical development pipeline to publicly traded company; Enveric now engaging with strategic advisors to identify and pursue alternative value-creating opportunities for cannabinoid assets Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of
The proposed spin-off would create two separate and distinct biotechnology companies, one developing next-generation psychedelic-inspired treatments and the other developing innovative cannabinoid treatments Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC') for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos Biosciences, Inc. (‘Akos'),
Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders Announced the expansion of patent protection for a broad range of molecules in its EVM301 portfolio, including five previously unannounced US patents Out-licensed patented radiation dermatitis topical product to Aries Science & Technology Out-licensed EVM201 Program including EB-002 Candidate to MycoMedica Life Sciences Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and
Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogen small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that the Company has executed a licensing agreement with MycoMedica Life Sciences, out-licensing the Company's EVM201 program, including drug candidate EB-002. Pursuant to the terms of licensing agreement, MycoMedica will seek to develop EB-002, formerly EB-373, a synthetic prodr
New patents expand the number and type of compounds available for development and the possible indications targeted, increasing the potential value of Enveric's drug candidate library Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announces the expansion of patent protection for a broad range of molecules in its EVM301 portfolio through the issuance of five additional US patents and the recent allowance of three more patent applications by the United States Patent and Trademark Office. The U.S. Patent Nos. 11,845,727; 11,858,895; 11,891,359;
Aegis Capital downgraded Enveric Biosciences from Buy to Hold and set a new price target of $0.20 from $7.00 previously
Aegis Capital initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $7.00
Maxim Group initiated coverage of Enveric Biosciences with a rating of Buy and set a new price target of $6.00
4 - Enveric Biosciences, Inc. (0000890821) (Issuer)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)
SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)